MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.
about
Cell-free and cellular activities of a DNA sequence selective hairpin polyamide-CBI conjugateMolecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agentsDesign, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative PropertiesAIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines.Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: structure-activity relationships.The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulationPrimary cilia are decreased in breast cancer: analysis of a collection of human breast cancer cell lines and tissuesDiscovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agentsSuppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhPoly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation.Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptorPelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancerUsing Pharmacokinetic Profiles and Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Early Signaling Changes Following Integrin-Linked Kinase Inhibition in an In Vivo ModelDiscovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties.Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumorsQLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatmenA high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity.Alginate-based microfluidic system for tumor spheroid formation and anticancer agent screening.A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells.Gene 33 inhibits apoptosis of breast cancer cells and increases poly(ADP-ribose) polymerase expression.Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy.A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines.Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models.In vivo model systems in P-glycoprotein-mediated multidrug resistance.IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells.Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
P2860
Q28219094-B57D5A15-7E8D-4B3B-B8A8-CC1464FF0D96Q28304646-BACC0E53-3547-49F9-B5C1-A6C72AF9F71BQ28548275-7682A436-D8C5-4C27-8248-C3A5EA82FDA7Q33241980-EB07CEC5-9672-4706-AD30-130E9723A757Q33376047-656A9C3B-3073-4438-BFE9-A4AC5DF53537Q33418462-E102EDA4-BEFA-4911-9B41-C9B43EFA4472Q33745823-D278CC65-9D39-439A-8D8D-727A501EDF07Q33818935-4803DD09-3C33-46FC-B7D9-0027AD7304C2Q34141711-C3A138F2-A2DD-46F2-9880-104B1151F994Q34240999-BF81D026-47C5-492C-90AF-465928DE0305Q34430583-8FE9C135-70EC-4098-B2E4-AF17476F53E4Q35001420-F781B2C0-302C-472F-8493-4E6B0B849B96Q35775850-1A5B2C24-9467-4686-9054-400A7A5D57C9Q35910960-34C80918-B1B1-4D23-8E2A-6D9E8F0DA5C3Q35978108-B9ADA6CA-1182-4DAA-9B30-085FB484C517Q36720975-DA082B68-406A-4FE5-BF93-1486EBCCBF49Q36890401-18DBDCEA-D9A4-47C6-B720-E88265B7720EQ37247862-F99D291B-4403-4CCB-B928-157371F544DCQ37277114-3BD78F96-7D9B-47EC-BB8F-B93EE061D48AQ39675117-FA9677A4-8E62-4648-B0C3-14ACA521DE44Q39890831-0B07CA65-CF8C-47B6-BDF4-7B38F4D183C6Q40265140-11CF9632-D390-40B7-8E7A-A0CC73E4E42CQ40410504-C0BE1D16-9AA3-4A36-9AF0-166C85915263Q40511781-8DF6CA45-BE21-4F82-8961-FB1CC1637FCBQ40616617-EC390BF9-A359-4E88-8E87-01003E68D030Q40769212-0A339531-D0A7-4E55-A149-836452CD9F5EQ41523907-6B062452-17F7-42F9-9C2D-19C571A38825Q41710325-ECAB5163-D72E-4802-AE84-6864F90BD599Q41734226-4523FD38-5B1E-4E57-8BD8-1411AF81844EQ42831886-456BA6F2-F4B9-4A60-A688-75F28E2138C9Q43706843-E0CDA32F-F645-442A-B4E2-95165CE3C8BAQ43811861-561F0224-1A5D-4252-B851-EFDD9DCE2917
P2860
MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.
@ast
MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.
@en
type
label
MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.
@ast
MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.
@en
prefLabel
MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.
@ast
MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer.
@en
P2093
P2860
P356
P1476
MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer
@en
P2093
F Leonessa
K Wingate-Legette
M M Gottesman
P2860
P2888
P304
P356
10.1038/BJC.1996.29
P407
P577
1996-01-01T00:00:00Z